All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

D. Hughes, D.A. Hughes, [No Value] All Wales Strategy Group.

Research output: Book/Report › Commissioned report

Cite this

@book{a9151dddffcd42f4b6bded608693d257,

title = "All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel{\textregistered}) Lymphoid blast CML and PH+ ALL.",

author = "D. Hughes and D.A. Hughes and \{All Wales Strategy Group.\}, \{[No Value]\}",

year = "2007",

month = jan,

day = "1",

language = "English",

publisher = "Unknown",

edition = "2007",

}

TY - BOOK

T1 - All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

AU - Hughes, D.

AU - Hughes, D.A.

AU - All Wales Strategy Group., [No Value]

PY - 2007/1/1

Y1 - 2007/1/1

UR - http://www.wales.nhs.uk/sites3/Documents/371/FAR%20dasatinib%20(Sprycel)%20PH%2BALL.pdf

M3 - Commissioned report

BT - All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

PB - Unknown

ER -